 Hyperlipoproteinemia Type II
"Hyperlipoproteinemia Type II" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A group of familial disorders characterized by elevated circulating cholesterol contained in either LOW-DENSITY LIPOPROTEINS alone or also in VERY-LOW-DENSITY LIPOPROTEINS (pre-beta lipoproteins).
| Descriptor ID |
D006938
|
| MeSH Number(s) |
C16.320.565.398.481 C18.452.584.500.500.644.475 C18.452.648.398.481
|
| Concept/Terms |
Hyperlipoproteinemia Type II- Hyperlipoproteinemia Type II
- Hyperlipoproteinemia Type IIs
- Hyper-Low Density Lipoproteinemia
- Density Lipoproteinemia, Hyper-Low
- Density Lipoproteinemias, Hyper-Low
- Hyper Low Density Lipoproteinemia
- Hyper-Low Density Lipoproteinemias
- Lipoproteinemia, Hyper-Low Density
- Lipoproteinemias, Hyper-Low Density
- Hyper-Low-Density-Lipoproteinemia
- Hyper-Low-Density-Lipoproteinemias
- Hyperlipoproteinemia, Type II
- Hyperlipoproteinemias, Type II
- Type II Hyperlipoproteinemia
- Type II Hyperlipoproteinemias
- Hypercholesterolemia, Essential
- Essential Hypercholesterolemia
- Essential Hypercholesterolemias
- Hypercholesterolemias, Essential
- Hypercholesterolemia, Familial
- Familial Hypercholesterolemia
- Familial Hypercholesterolemias
- Hypercholesterolemias, Familial
- Hypercholesterolemic Xanthomatosis, Familial
- Familial Hypercholesterolemic Xanthomatoses
- Familial Hypercholesterolemic Xanthomatosis
- Hypercholesterolemic Xanthomatoses, Familial
- Xanthomatoses, Familial Hypercholesterolemic
- Xanthomatosis, Familial Hypercholesterolemic
- Hyperlipoproteinemia Type 2
- Hyperlipoproteinemia Type 2s
- Type 2, Hyperlipoproteinemia
- Hyper-beta-Lipoproteinemia
- Hyper beta Lipoproteinemia
- Hyper-beta-Lipoproteinemias
- Hyperbetalipoproteinemia
- Hyperbetalipoproteinemias
Hyperlipoproteinemia Type IIb- Hyperlipoproteinemia Type IIb
- Hyperlipoproteinemia Type IIbs
- Hypercholesterolemia, Autosomal Dominant, Type B
- Familial Combined Hyperlipoproteinemia
- Combined Hyperlipoproteinemia, Familial
- Combined Hyperlipoproteinemias, Familial
- Familial Combined Hyperlipoproteinemias
- Hyperlipoproteinemia, Familial Combined
- Hyperlipoproteinemias, Familial Combined
- Apolipoprotein B-100, Familial Defective
- Apolipoprotein B 100, Familial Defective
- Apolipoprotein B-100, Familial Ligand-Defective
- Apolipoprotein B 100, Familial Ligand Defective
Hyperlipoproteinemia Type IIa- Hyperlipoproteinemia Type IIa
- Hyperlipoproteinemia Type IIas
- Hyperlipoproteinemia, Type IIa
- Hyperlipoproteinemias, Type IIa
- Type IIa Hyperlipoproteinemia
- Type IIa Hyperlipoproteinemias
- Hypercholesterolemia, Autosomal Dominant
- Autosomal Dominant Hypercholesterolemia
- Autosomal Dominant Hypercholesterolemias
- Dominant Hypercholesterolemia, Autosomal
- Dominant Hypercholesterolemias, Autosomal
- Hypercholesterolemias, Autosomal Dominant
- LDL Receptor Disorder
- Disorder, LDL Receptor
- Disorders, LDL Receptor
- LDL Receptor Disorders
- Receptor Disorder, LDL
- Receptor Disorders, LDL
|
Below are MeSH descriptors whose meaning is more general than "Hyperlipoproteinemia Type II".
Below are MeSH descriptors whose meaning is more specific than "Hyperlipoproteinemia Type II".
This graph shows the total number of publications written about "Hyperlipoproteinemia Type II" by people in this website by year, and whether "Hyperlipoproteinemia Type II" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2005 | 1 | 0 | 1 | | 2006 | 0 | 1 | 1 | | 2007 | 1 | 1 | 2 | | 2011 | 3 | 0 | 3 | | 2012 | 1 | 1 | 2 | | 2015 | 2 | 0 | 2 | | 2016 | 1 | 1 | 2 | | 2017 | 1 | 0 | 1 | | 2019 | 1 | 2 | 3 | | 2020 | 2 | 0 | 2 | | 2021 | 2 | 0 | 2 | | 2023 | 1 | 0 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Hyperlipoproteinemia Type II" by people in Profiles.
-
Daniels SR. What Is the Optimum Approach to Screening for Familial Hypercholesterolemia in Children? JAMA Pediatr. 2023 06 01; 177(6):565-566.
-
de Ferranti SD, Kazi DS, Bibbins-Domingo K, Daniels S, Howaniec B, Khera AV, Newman TB, Vernacchio L. Perspectives on Identifying and Treating Familial Hypercholesterolemia in Childhood. Clin Chem. 2021 10 01; 67(10):1312-1317.
-
Wright RS, Ray KK, Raal FJ, Kallend DG, Jaros M, Koenig W, Leiter LA, Landmesser U, Schwartz GG, Friedman A, Wijngaard PLJ, Garcia Conde L, Kastelein JJP. Pooled Patient-Level Analysis of Inclisiran Trials in Patients With Familial Hypercholesterolemia or Atherosclerosis. J Am Coll Cardiol. 2021 03 09; 77(9):1182-1193.
-
Daniels S, Caprio S, Chaudhari U, Manvelian G, Baccara-Dinet MT, Brunet A, Scemama M, Loizeau V, Bruckert E. PCSK9 inhibition with alirocumab in pediatric patients with heterozygous familial hypercholesterolemia: The ODYSSEY KIDS study. J Clin Lipidol. 2020 May - Jun; 14(3):322-330.e5.
-
Puri R, Mehta V, Duell PB, Nair D, Mohan JC, Yusuf J, Dalal JJ, Mishra S, Kasliwal RR, Agarwal R, Mukhopadhyay S, Wardhan H, Khanna NN, Pradhan A, Mehrotra R, Kumar A, Puri S, Muruganathan A, Sattur GB, Yadav M, Singh HP, Agarwal RK, Nanda R. Proposed low-density lipoprotein cholesterol goals for secondary prevention and familial hypercholesterolemia in India with focus on PCSK9 inhibitor monoclonal antibodies: Expert consensus statement from Lipid Association of India. J Clin Lipidol. 2020 Mar - Apr; 14(2):e1-e13.
-
Daniels SR. Screening for Familial Hypercholesterolemia. JAMA Cardiol. 2019 07 01; 4(7):689-690.
-
Robinson JG, Jayanna MB, Brown AS, Aspry K, Orringer C, Gill EA, Goldberg A, Jones LK, Maki K, Dixon DL, Saseen JJ, Soffer D. Enhancing the value of PCSK9 monoclonal antibodies by identifying patients most likely to benefit. A consensus statement from the National Lipid Association. J Clin Lipidol. 2019 Jul - Aug; 13(4):525-537.
-
Braun LT, Saseen JJ, Orringer CE, Stone NJ, Guyton JR. JCL roundtable. The 2018 AHA/ACC/Multisociety Cholesterol Guidelines: Process and product. J Clin Lipidol. 2019 May - Jun; 13(3):345-355.
-
Daniels SR. How to identify children with familial hypercholesterolemia. J Pediatr. 2017 04; 183:2.
-
Stempel H, Dodge A, Marriott E, Peterson AL. Referral Patterns and Cascade Screening for Familial Hypercholesterolemia in a Pediatric Lipid Clinic. J Pediatr. 2016 Nov; 178:285-287.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|